Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28031560
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28031560
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Nat+Rev+Clin+Oncol
2017 ; 14
(6
): 335-346
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
The landscape of new drugs in lymphoma
#MMPMID28031560
Younes A
; Ansell S
; Fowler N
; Wilson W
; de Vos S
; Seymour J
; Advani R
; Forero A
; Morschhauser F
; Kersten MJ
; Tobinai K
; Zinzani PL
; Zucca E
; Abramson J
; Vose J
Nat Rev Clin Oncol
2017[Jun]; 14
(6
): 335-346
PMID28031560
show ga
The landscape of drugs for the treatment of lymphoma has become crowded in light
of the plethora of new agents, necessitating the efficient prioritization of
drugs for expedited development. The number of drugs available, and the fact that
many can be given for an extended period of time, has resulted in the emergence
of new challenges; these include determining the optimal duration of therapy, and
the need to balance costs, benefits, and the risk of late-onset toxicities.
Moreover, with the increase in the number of available investigational drugs, the
number of possible combinations is becoming overwhelming, which necessitates
prioritization plans for the selective development of novel combination regimens.
In this Review, we describe the most-promising agents in clinical development for
the treatment of lymphoma, and provide expert opinion on new strategies that
might enable more streamlined drug development. We also address new approaches
for patient selection and for incorporating new end points into clinical trials.
|Antineoplastic Agents/*therapeutic use
[MESH]
|Antineoplastic Combined Chemotherapy Protocols/therapeutic use
[MESH]
free
free
free
